Sovereign Metals signs premium rutile offtake agreement

Sovereign Metals have signed an offtake MOU for their world class Kasiya titanium rutile project in Malawi.

Sovereign Metals said they have signed a memorandum of understanding with Hascor, a market leading global processor and distributor of rutile products for the welding industry.

The MOU would see a supply of 25,000 tonnes of natural rutile per annum delivered to Hascor which has processing plants across five continents.

Rutile prices of offtake destined for the welding industry generally demand a premium when compared to rutile used in pigments.

The MOU is non-exclusive and non-binding and is subject to ongoing negotiations. The MoU will expire on 31 December 2023 but has the option to be extended.

“We are very excited to have signed this MoU with a major rutile supplier like Hascor about a future offtake agreement and to provide input on marketing for our premium rutile products from Kasiya,” said Sovereign’s Managing Director Dr Julian Stephens.

“Hascor is a market leader in natural rutile product development and distribution for the welding industry across five continents. The offtake MoU with Hascor points to the quality and strategic nature of our world-class Kasiya Rutile Project.”

The global rutile market currently demands 2.8mt per annum and Sovereign Metals is well placed to serve this market with the Kasiya project, the world’s largest undeveloped Rutile resource.

Why investors should look at Croda International shares

0

Investors might want to consider Croda shares after the stock dropped to 7,138p from its high of 10,100p at the beginning of the year.   

This is a significant drop for a company that has consistently posted increased dividends over the past ten years and recently said they enjoyed a 46.6% increase in operating profit in 2021.

Croda International Share Price 

Croda shares are currently trading at 7,138p – the lowest level since 24 February 2022 – having fallen from recent highs of approximately 7,484p. The stock is down 30% year-to-date.

“This is not the company’s fault. It’s just the result of the stock’s lofty valuation and investors’ ongoing switch away from highly-rated growth stocks at a time of rising interest rates and toward commodity and raw materials plays at a time of rising prices and inflation,” said AJ Bell Investment Director Russ Mould.

The drop in price potentially represents an interesting opportunity for investors who see value in the company’s strong financial results. 

Croda International saw an increase in operating profit of 46.6% to £468.6 million against a 2020 figure of £319.6 million.   

The Group’s profit before tax was £445.2 million in 2021 against a result of £300.6 million in 2020.   

The company reported that all its businesses were trading ahead of pre-Covid-19 pandemic levels, and saw growth in areas including life sciences and from its recent acquisitions. 

However, Croda International shares have experienced a decline due to its pipeline of 150 Covid-19 related projects, in addition to a further 90 throughout 2021 falling in relevancy as the rates of international vaccination increased.

Expectations for 2022

The company’s growth is predicted to continue in line with its medium-term expectations.  

Croda International expects strong consumer demand, inflation cost recovery and the benefit of its recent investments to offset moderation in customer restocking.  

Following the sale of Croda’s performance technologies and industrial chemicals businesses (PTIC) to agricultural production company Cargill for £778 million, the Group is apparently set to streamline its business and give the company an increased level of capital to reinvest in its upcoming growth.  

“[The deal] will release more capital to reinvest in faster growth, higher return markets, positioning us to deliver more consistent sales growth and an even stronger profit margin,” said Croda International CEO Steve Foots.  

Croda International’s dividend  

Croda International’s statutory basic earnings per share in 2021 saw an increase of 48.3% to 230p compared to 155p in 2020.  

The company’s ordinary dividend per share increased 9.9% to 100p against a figure of 91p in 2020.  

The Group has seen a healthy dividend progression over the past two years, with increased returns to shareholders year on year.  

the Croda share price currently provides a dividend yield 1.4%.

Is the HSBC share price attractive at this level?

0

Despite the recent announcement of buy backs and reduction of impairment charges leading to a jump in profits, HSBC shares have since sank on geopolitical concerns.

The recent drop in the HSBC share price will get the attention investors who will likely be questioning whether now is a good time to buy HSBC shares?

HSBC Share Price

Year to date, HSBC shares peaked in mid February at 567p and now trade at 504p, up 12% on the year.

Although HSBC posted good results, shares have declined due to geopolitical risks and concerns around the company’s outlook.

With the geopolitical risk around the Russia conflict sending waves through the financial system, there is a significant chance HSBC shares face further volatility in the coming weeks.

This is due to the global nature of HSBC’s operations and complexities of the financial system. Sanctions on Russia will likely have a greater impact on HSBC, when compared to domestic focused banks such as Lloyds and Natwest.

HSBC Earnings

HSBC announced a rise in profit after tax of $8.6bn to $14.7bn for 2021, and a profit before tax of $10.1bn to $18.9bn in 2021.

The profits had a positive impact due to impairment charges being reversed and bad debt provisions being reduced. The impairment charges for HSBC saw a steep decline from $8.8bn in 2020 to $0.9bn in 2021 which had a positive impact on the banks profitability.

However HSBC were forced to set aside cash to provide for any adverse scenario in the Chinese property markets. Analysts highlighted this as one of the major concerns for investors going forward.

“China’s property woes clearly remain a cause for concern for the Asia focused bank. The market is having a less than savoury response to higher than expected impairment charges, a lot of which relates to uncertainty in the Chinese commercial real estate sector,” said Susannah Streeter, senior investment and market analyst, Hargreaves Lansdown shortly after the release of HSBC’s results in February.

Net Interest Margin

Streeter also highlighted the precarious nature of HSBC’s business in a world that is starting to rate rises, but also relies on lendng activities across multiple geographies.

“The Goldilocks dilemma is also evident in this update, as HSBC needs inflation to tick up enough to prompt rising rates, but not be so hot it makes customers nervous about taking on new borrowing, which could dent its loans business,” Streeter said.

HSBC announced a decline in group in net interest income in 2021 with net interest margin decreasing 12 basis points to 1.2%.

Lower margins were a result of UK bank base rate cuts in 2020, as well as increased quantities of client deposit balances and cash at central banks.

With the ongoing situation in Ukraine, UK banks might miss out higher net interest margins, if the Bank of England – and other central banks – hold back from a steep tightening cycle.

HSBC Dividends

HSBC investors will be happy to see dividends increase to $0.25 per share for the full year. HSBC now has dividend yield of 3.7%.

HSBC Shares Valuation

With the HSBC share price are trading at 508p, the stock has a forward P/E of 9.39x and trailing P/E of 11.13x which is significantly above FTSE 100 banking peers.

This will reflect their global operations but seems rich given ongoing geopolitical risks.

Palace Capital surpasses targets on strategic disposal

1

Palace Capital were able to exceed the goals set on strategic disposal with the sale of Pelhan House in Brighton.

Palace Capital is property investment firm. The group’s portfolio is filled with handpicked commercial real estate in the UK. The location of the real estate units are mainly outside of London, with a concentration in the office and industrial sector.

On Thursday, Palace Capital declared the completion of the disposal of their asset, Pelham House. Pelham House is in Pelham Square located within Brighton. The sale generated £1.6m.

A strategic disposal plan was established by the property investment firm in April of 2021. Fifteen non-essential properties were established for disposal, which would yield an income of £30m minimum. With the sale of Pelham House, which is the 14th of the 15 properties to be sold off, the group has enjoyed £31.5m in total consideration from the sales programme.

The current income collected from the sale of the 14 assets is exceeding the aggregate book value by 20% and the previous procurement rate inclusive of capital expenditure by 12%.

From the proceeds, £15.7m have been utilised in paying off debt. The remainder of £15.8m will be used in reinvestments of assets which are in line with the firms needs.

“These sales at 20% above book value have generated an ungeared 11% aggregated IRR for shareholders which with our continuing Hudson Quarter apartment sales, have further strengthened our balance sheet,” said Neil Sinclair, Chief Executive, Palace Capital.

“Following the recent acquisition and letting activity, new income exceeds the rent lost through disposals, resulting in fewer but better quality properties. With a pipeline of potential opportunities, we look forward to updating the market on further acquisitions in due course as we continue to recycle capital.”

ITV shares sink on launch of new streaming service

0

ITV reported a 28% increase in revenue of £1.76 billion against a 2020 figure of £1.37 billion as it released a wave of strong financial results.

The entertainment company saw an adjusted EBITA of £813 million against a £573 million result in 2020.

ITV further reported an operating profit of £519 million compared to £356 million in 2020.

“ITV Studios has enjoyed both ratings and critical success and currently has around 500 programmes in production in the UK and internationally,” said ITV CEO Carolyn McCall.

“Media and Entertainment kept viewers and advertisers alike happy with a compelling slate of entertainment shows and dramas and must watch sport across ITV’s channels and streaming.”

The company also highlighted its 2022 target launch of its new ITVX, the first integrated AVOD/SVOD streaming platform across the UK.

“With the success of ITV Hub, ITV Hub+, Planet V and BritBox we see an exciting opportunity to at least double our digital revenues to £750m by 2026,” said McCall.

“At its heart will be ITVX – the first integrated AVOD/SVOD streaming platform in the UK.  It will be a seamless viewer experience with a digital first content and windowing strategy and significant content investment providing weekly premieres and over 15,000 hours of content at launch.”

“This will enable ITV to double streaming viewing, double monthly active users, double subscribers and deliver valuable addressable advertising inventory at scale.”

ITV said that the launch of its ITVX service in 2022 is estimated to help double the company’s digital revenues to £750 million by 2026.

However, analysts pointed to the costs associated with the new service and lack of innovation as reason for investor concerns on Thursday.

“ITVX is not as revolutionary as the company might like you to believe. It is effectively offering viewers a chance to see some of its programmes before they are broadcast on linear TV as well as its back catalogue of shows,” said AJ Bell investment director Russ Mould.

ITV’s share price dropped 13.7% to 95.4p on Thursday morning trading despite the strong financial results.

Mondi delivers 28% increase in profit before tax

0

Mondi’s profit before tax grew 28% to €983m in 2021 as growth accelerated for their sustainable packaging offering.

The group’s revenue saw a rise of 16% from €6.6bn in 2020 to €7.7bn in 2021. Underlying EBITDA increased to €1.5bn from €1.3bn YoY.

The groups financial performance was a reflection of higher sales volumes due to growth in demand for corrugated packing and flexible packing. Selling prices of the products were also increased to compete with inflationary cost burdens. The highest result in new selling prices came from corrugated packaging.

To encourage the growth trend in the packaging markets, a significant lineup for capital investments have been set up, including €1 billion in expansionary projects that have been authorised or are being evaluated.

Strong financials of the group lead the board to recommend an increase in full year dividends grew 8% from €0.60 to €0.65 YoY.

ESG

ESG measures launched Mondi Action Plan 2030, which is a sustainability roadmap. The company will continue to focus on climate resilience, zero deforestation in its wood supply, procuring wood sustainably from healthy and resilient forests, and protecting biodiversity and water resources in its activities and beyond as part of the MAP2030 strategy.

The group has committed to working towards the 1.5°C event with the goal of Net-Zero by 2050.

Sale of Business

Divestment of their business, personal care components (PCC), created an enterprise value of €615m. Due to Mondi’s strategic approach on packaging and PCC’s low overlap with the rest of the company, they felt that the next phase of PCC’s development will be best carried out from outside the Group.

The group has major activities in Russia, which will account for roughly 12% of Mondi’s sales in 2021. They also have a plant in Syktyvkar, which is a high-margin, cost-competitive integrated pulp, packaging paper, and uncoated fine paper mill. Russia accounts for 20% of group EBITDA.

“Mondi delivered strongly in 2021 and we see good opportunity to accelerate growth in sustainable packaging. Underlying EBITDA of €1,503 million was up 11% and ROCE up at 16.9%. We grew our packaging businesses and saw a recovery in uncoated fine paper markets. Our vertical integration, the agility of our operations and collaboration with our customers ensured we met surging demand at a time when supply chains were under pressure around the world. We implemented price increases across all our businesses and, against a backdrop of rising commodity input costs, we exhibited good cost control. Our focus on safety and protecting the wellbeing of our people remains our priority,” commented Andrew King, Chief Executive Officer, Mondi Group.

Mondi shares are trading down 1.9% at 1491p post the open on Thursday morning.

Tyman plc announce record 12.9p per share dividend

1

Tyman plc saw its share price rise 3.4% to 365p after it reported strong financial results on Thursday morning.

The company enjoyed a 17% increase in revenue to £635.7 million against a figure of £572.8 million in 2020.

Tyman reported an adjusted operating profit of £90 million against an £80.3 million result in 2020, alongside a pre-tax profit of £64 million compared to its £47.6 million figure in 2020.

The home products company said an increase in market share and strengthen demand helped boost revenue.

Investors also saw a record dividend per share of 12.9p against a payment of 4p in 2020.

Tyman commented that it had achieved its performance goals despite industry-wide challenges to its supply chain, alongside labour restrictions and input cost inflation.

“The Group’s performance was robust, with strong market momentum and share gains delivering growth in spite of well-publicised supply chain challenges, labour constraints and input cost inflation,” said Tyman CEO Jo Hallas.

“We expect underlying demand in 2022 to remain strong, driven by favourable housing market fundamentals, albeit set against rising macroeconomic and geopolitical pressures.”

“We continue to take actions as necessary to mitigate ongoing industry-wide supply chain challenges and cost inflation.”

“The Group is well positioned for growth in 2022 and beyond, benefiting from long-term structural industry growth drivers, our strategic initiatives and building on our portfolio of differentiated products, market-leading brands and deep customer relationships. “

Lloyds share price: an opportunity for long term investors

The Lloyds share price has provided investors with an opportunity to enter the UK banks following a sharp decline from highs of 56p.

For long-term investors, the recent pull back in Lloyds shares, coupled with their recent market update, may create the perfect scenario for those considering a purchase of the bank’s shares.

Lloyds share price

Lloyds shares are currently trading just above 45p – the lowest level since December 2021 – having dropped nearly 20% from recent highs around 55p.

This dip will provide a great opportunity for investors who have digested Lloyds recent report and are optimitic about their outlook.

Lloyds reported a 9% increase in Net Income to £15.8bn and enjoyed a rise in return on tangible equity to 13.8%.

This reflected an improvement in trading conditions in 2021 as the bank recovered from the pandemic.

Lloyds reported a statutory profit before tax of £6.9 billion and statutory profit after tax of £5.9 billion which was helped by increased income and the reversal of bad debt provisions made during the pandemic.

Lloyds also said they were hoping to put the HBOS issues to bed by making provisions for the total estimated cost of charges.

However, Lloyds shares have since plummeted, not solely because of disappointment around their earnings, but the impact of geopolitics on markets and interest rate expectations.

Lloyds Net Interest Margin

Lloyds saw Net Interest Income rise 4% to £11.2 billion in 2021 and there will be expectations this increases further in 2022.

This argument can be justified by the expectations of higher interest rates, and because of recent strong performance in their lending business.

Lloyds saw their Net Interest Margin rise to 2.54% in 2021 from 2.52% in the year prior.

Although the crisis in Ukraine may dampen the Bank of England’s enthusiasm for the number of interest hikes in 2022, Lloyds will already be enjoying the impact of two rates hikes in recent months.

Lloyds dividend

Notwithstanding hopes for increased earnings, an important attraction for long-term holders of Lloyds shares is the banks progressive dividend policy.

Lloyds paid a dividend of 2p for 2021 which would equate to a 4.4% yield with Lloyds share price at 45p.

Given Lloyds are once more embarking on a progressive dividend policy as the impact of the pandemic diminishes, buyers at 45p will likely see their yield increase as dividend payouts rise.

Lloyds Shares Valuation

With a Lloyds share price of 45p, the bank is trading at just 5.9x historical earning and 7.1x forward earnings.

Although UK banks are increasingly valued on their price-to-book multiples, the potential for Lloyds PE Ratio to move back inline with historical averages suggests Lloyds shares have plenty of upside.

Allergy Therapeutics on course to relieve hay fever and peanut allergies

0

Allergy Therapeutics delivered substantial update on pollen and peanut allergy remedies at a US industry gathering.

Allergy Therapeutics is a completely integrated commercial biotechnology company focused on allergy vaccines. The Group is focused on allergens that can be treated with subcutaneous and sublingual immunotherapy like, pollens, house dust mites, pets and moulds.

At the 2022 American Academy of Allergy, Asthma, and Immunology Annual Meeting in Phoenix, Arizona, the group delivered promising new results from its two lead immunotherapy programmes.

Allergy Therapeutics Update

Allergy Therapeutics reported extensive results from the G309 exploratory field study, indicating safety and effectiveness of Grass MATA MPL, the Group’s short-course injectable allergen-specific immunotherapy (SCIT) candidate for allergic rhinoconjunctivitis caused by grass pollen. This was a multi-centre, double-blind, placebo-controlled, randomised and parallel-group clinical experiment with participants from 13 different locations in Germany and the United States.

In comparison to the historically used placebo group’s effective dose on the clinical outcome, the presentations disclosed a more prominent, clinically significant, and statically relevant progress in the primary combined symptom and medication score for the conventional and extended posology groups, respectively.

This increase of 39.5% is higher than the estimated number of 36.8% announced by the Group in October2021, when the two placebo groups were pooled. These findings indicate the superior treatment effect sizes reached after six Grass MATA MPL injections.

The Group also provided post-hoc analyses of a previous Phase II grass trial, showcasing the robust prognosis of the baseline CPT (conjunctival provocation test) score for IgG4 increase after SCIT treatment, laying the groundwork for the impending vital G306 Phase III trial, which will begin in the autumn of 2022.

The company also released information of a pollen monitoring network set up by Allergy Therapeutics in the U. S., complete with central reading procedures for correctly estimating daily pollen counts and determining the peak grass pollen season, which is crucial for determining the G306 Phase III trial’s primary study results.

Dr. Mohamed Shamji, an Imperial College London Reader in Immunology and Allergy, delivered findings from the VLP001 ex-vivo biomarker study.

The study looked at the group’s peanut allergy vaccine candidate, VLP Peanut. When compared to the predominant allergen, Ara h2, the data indicated that VLP Peanut is a hypoallergenic, and leads in a considerable reduction in basophil activation and histamine release in peanut allergic people. These biomarker results show significant help for VLP Peanut’s possible immunologic mode of action in encouraging transferring from the allergic Th2 pathway to the more immunological tolerant Th1 pathway, highlighting VLP Peanut’s potential as a peanut allergy treatment.

Company Vaccine Portfolio

The Group has a vast variety of vaccines at different stages of the pipeline.

The vaccines cater to two forms of therapy which are Modified Allergen Tyrosine Adsorbed (MATA) and Subcutaneous Immunotherapy (SCIT).

Allergy Therapeutics have a handful of drugs which are already on the market or registered which include, hay fever meds, bee and wasp remedies. Peanut allergy remedies are still under Phase 1.

“Demonstrating a nearly 40% reduction in combined symptom and medication score compared to placebo in a grass pollen allergy trial is a significant event in our history. We are very much looking forward to the pivotal G306 clinical trial of our Grass MATA MPL immunotherapy that is due to commence later this year and, if successful, would enable registration in Europe and the US. Such a product would permit patients suffering from grass pollen allergy the opportunity to address the cause of their disease, not just mask their symptoms. I am also very proud to see the data from our VLP001 study being presented internationally – data that provides us with confidence in the product profile of our novel short course peanut allergy vaccine candidate as we head into the clinic later this year,” said Manuel Llobet, Chief Executive Officer, Allergy Therapeutics.

ECR minerals continue to strike gold

ECR minerals shared good news regarding the result of hole BH3DD019 drilled into the north end of the Maori Reef inside HR3 at Bailieston, Victoria.

ECR minerals is a gold exploration and development company based in Australia. HR3 is completely owned by ECR minerals.

BH3DD019

Hole BH3DD019 is one of four holes designed to crosscut H43 goldfield. The series of the four holes entail BH3DD012, BH3DD014, BH3DD020, and BH3DD021. Due to staffing issues during the pandemic, the drills and tests were put on hold. However, post recovery of the pandemic, the results from BH3DD019 are in.

Results

Four mineralisation zones have been found in BH3DD019 from tests taken on the drill hole. This is the deepest hole dug beneath the Maori Reef’s north end. The outcome declares findings of further deposits of gold. The presence of visible stibnite in holes drilled into the Maori Reef corresponds with the likelihood of finding gold.

Stibnite, arsenopyrite, and gold mineralisation are all part of a ‘epizonal’ form of mineralisation encountered in surrounding deposits including Costerfield, Nagambie, and Whroo.

The findings include 0.5m @ 9.5 g/t Au from 99.9m, 0.8m @ 4.96 g/t Au from 100.4m, 0.3m @ 4.59 g/t Au from 143.4m and 0.6m @ 6.15 g/t Au from 231.5m.

“I am delighted to report that our team of geologists headed by Adam Jones are reporting some very encouraging gold grades at hole BH3DD019. Furthermore, the epizonal mineralisation identified through the drilling work and assay results correlates with nearby deposits at Costerfield, Nagambie and Whroo mine and this is assisting with our understanding of the regional gold trend as we work towards identifying a possible ore resource,” stated David Tang, Chairman, ECR.

ECR shares were trading down at 0.21% to 1.4p on Wednesday.